Papivax Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 3


  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 2

Papivax General Information


Developer of immunotherapies intended for chronic viral infections. The company focuses on immunotherapy for infections and related cancers with Phase II assets in HPV infection and HPV-related cancers, enabling patients with safe and effective treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Corporate Office
  • 1812 Ashland Avenue
  • Suite 110
  • Baltimore, MD 21205
  • United States
+1 (301) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Papivax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Grant 01-Jun-2014 $588K Completed Generating Revenue
To view Papivax’s complete valuation and funding history, request access »

Papivax Patents

Papivax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022200326-A1 Vaccine combination and method for using the same Pending 19-Jan-2022 000000000
US-20230226164-A1 Vaccine combination and method for using the same Pending 18-Jan-2022 000000000
CA-3145936-A1 Vaccine combination and method for using the same Pending 18-Jan-2022 000000000
JP-2023104815-A Combination of vaccines and method for use thereof Active 18-Jan-2022
US-20220160865-A1 Dna vaccine for human papillomavirus and method for using the same Active 24-Nov-2020 A61P35/00 0
To view Papivax’s complete patent history, request access »

Papivax Executive Team (4)

Name Title Board Seat Contact Info
Lily Wu President, Chief Executive Officer & Chairman
Connie Lai Finance Manager
Yung-Nien Chang Ph.D Chief Scientific Officer
You’re viewing 3 of 4 executive team members. Get the full list »

Papivax Board Members (6)

Name Representing Role Since
Alan Lu Self Board Member 000 0000
Kou Yuan Chen Self Board Member 000 0000
Kun-Yang Chuang Ph.D Self Board Member 000 0000
Kuo-Tai Chuang MD Self Board Member 000 0000
M. Joe Ma Ph.D Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Papivax Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Papivax Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cancer Research Horizons Venture Capital Minority 000 0000 000000 0
Johns Hopkins Technology Ventures Accelerator/Incubator Minority 000 0000 000000 0
To view Papivax’s complete investors history, request access »

Papivax FAQs

  • When was Papivax founded?

    Papivax was founded in 2013.

  • Who is the CEO of Papivax?

    Lily Wu is the CEO of Papivax.

  • Where is Papivax headquartered?

    Papivax is headquartered in Baltimore, MD.

  • What is the size of Papivax?

    Papivax has 3 total employees.

  • What industry is Papivax in?

    Papivax’s primary industry is Drug Discovery.

  • Is Papivax a private or public company?

    Papivax is a Private company.

  • What is Papivax’s current revenue?

    The current revenue for Papivax is 00000.

  • Who are Papivax’s investors?

    Cancer Research Horizons and Johns Hopkins Technology Ventures have invested in Papivax.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »